<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Scourfield DO</submitter><funding>Kenneth Rainin Foundation</funding><funding>Versus Arthritis</funding><funding>Medical Research Council</funding><funding>Kennedy Trust</funding><funding>Wellcome Trust</funding><pagination>iqab003</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7928637</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2(1)</volume><pubmed_abstract>Coronavirus disease 2019 has generated a rapidly evolving field of research, with the global scientific community striving for solutions to the current pandemic. Characterizing humoral responses towards SARS-CoV-2, as well as closely related strains, will help determine whether antibodies are central to infection control, and aid the design of therapeutics and vaccine candidates. This review outlines the major aspects of SARS-CoV-2-specific antibody research to date, with a focus on the various prophylactic and therapeutic uses of antibodies to alleviate disease in addition to the potential of cross-reactive therapies and the implications of long-term immunity.</pubmed_abstract><journal>Oxford open immunology</journal><pubmed_title>The role and uses of antibodies in COVID-19 infections: a living review.</pubmed_title><pmcid>PMC7928637</pmcid><funding_grant_id>KENN202111</funding_grant_id><funding_grant_id>MR/M008614/2</funding_grant_id><funding_grant_id>G0000635</funding_grant_id><funding_grant_id>KRA000116</funding_grant_id><funding_grant_id>KENN161708</funding_grant_id><funding_grant_id>KENN202113</funding_grant_id><funding_grant_id>211122/Z/18/Z</funding_grant_id><funding_grant_id>KENN151606</funding_grant_id><funding_grant_id>21546</funding_grant_id><pubmed_authors>Compeer EB</pubmed_authors><pubmed_authors>Rodrigues PRS</pubmed_authors><pubmed_authors>Sami A</pubmed_authors><pubmed_authors>Selvakumar TA</pubmed_authors><pubmed_authors>Crespo AT</pubmed_authors><pubmed_authors>Simon AK</pubmed_authors><pubmed_authors>Oxford-Cardiff COVID-19 Literature Consortium</pubmed_authors><pubmed_authors>Lauder SN</pubmed_authors><pubmed_authors>Hanna SJ</pubmed_authors><pubmed_authors>Bezbradica JS</pubmed_authors><pubmed_authors>Cifuentes L</pubmed_authors><pubmed_authors>Dimonte S</pubmed_authors><pubmed_authors>Godkin A</pubmed_authors><pubmed_authors>Robinson AJB</pubmed_authors><pubmed_authors>Bayliss R</pubmed_authors><pubmed_authors>Thornton E</pubmed_authors><pubmed_authors>Dyer A</pubmed_authors><pubmed_authors>Issa F</pubmed_authors><pubmed_authors>Mazet JM</pubmed_authors><pubmed_authors>van Grinsven E</pubmed_authors><pubmed_authors>Ahern DJ</pubmed_authors><pubmed_authors>Alonzi DS</pubmed_authors><pubmed_authors>Borst R</pubmed_authors><pubmed_authors>Ligoxygakis P</pubmed_authors><pubmed_authors>Fischer F</pubmed_authors><pubmed_authors>Williams R</pubmed_authors><pubmed_authors>Smith AL</pubmed_authors><pubmed_authors>Schonfeldova B</pubmed_authors><pubmed_authors>Zhu Z</pubmed_authors><pubmed_authors>Hulin-Curtis S</pubmed_authors><pubmed_authors>Alrubayyi A</pubmed_authors><pubmed_authors>Jones E</pubmed_authors><pubmed_authors>Reed S</pubmed_authors><pubmed_authors>James Matthews R</pubmed_authors><pubmed_authors>Scourfield DO</pubmed_authors><pubmed_authors>Quastel M</pubmed_authors><pubmed_authors>Alsaleh G</pubmed_authors><pubmed_authors>Fielding C</pubmed_authors><pubmed_authors>Zhou D</pubmed_authors><pubmed_authors>Galloway S</pubmed_authors><pubmed_authors>Cross A</pubmed_authors><pubmed_authors>Gammage A</pubmed_authors><pubmed_authors>Capitani L</pubmed_authors><pubmed_authors>Sabberwal P</pubmed_authors><pubmed_authors>Borsa M</pubmed_authors><pubmed_authors>Uhl LFK</pubmed_authors><pubmed_authors>Shepherd FR</pubmed_authors><pubmed_authors>Peres RS</pubmed_authors><pubmed_authors>Marzeda AM</pubmed_authors><pubmed_authors>Liddiard K</pubmed_authors><pubmed_authors>Shorten C</pubmed_authors><pubmed_authors>Dendrou CA</pubmed_authors><pubmed_authors>MacLachlan B</pubmed_authors><pubmed_authors>Alderson J</pubmed_authors><pubmed_authors>Gallimore A</pubmed_authors><pubmed_authors>Mitchell E</pubmed_authors><pubmed_authors>Maleki-Toyserkani S</pubmed_authors><pubmed_authors>Nguyen VD</pubmed_authors><pubmed_authors>Burnell SEA</pubmed_authors><pubmed_authors>Richmond N</pubmed_authors><pubmed_authors>Berthold DL</pubmed_authors><pubmed_authors>Wilson JD</pubmed_authors><pubmed_authors>Eleonore Pavillet C</pubmed_authors><pubmed_authors>Peter Durairaj RR</pubmed_authors><pubmed_authors>Cavounidis A</pubmed_authors><pubmed_authors>Chauveau A</pubmed_authors><pubmed_authors>Davies LC</pubmed_authors><pubmed_authors>O'Hanlon M</pubmed_authors><pubmed_authors>Codd AS</pubmed_authors><pubmed_authors>Moon O</pubmed_authors><pubmed_authors>Coveney C</pubmed_authors><pubmed_authors>Lu F</pubmed_authors><pubmed_authors>Danielli S</pubmed_authors><pubmed_authors>Jones R</pubmed_authors><pubmed_authors>Bharuchq T</pubmed_authors><pubmed_authors>Sattentau Q</pubmed_authors><pubmed_authors>Heuberger C</pubmed_authors><pubmed_authors>Gea-Mallorqui E</pubmed_authors><pubmed_authors>Mann EH</pubmed_authors><pubmed_authors>Dustin LB</pubmed_authors><pubmed_authors>Pring E</pubmed_authors><pubmed_authors>Reed SG</pubmed_authors><pubmed_authors>Borrmann H</pubmed_authors><pubmed_authors>Pires A</pubmed_authors><pubmed_authors>Wann AKT</pubmed_authors><pubmed_authors>Teijeira Crespo A</pubmed_authors><pubmed_authors>Almuttaqi H</pubmed_authors><pubmed_authors>Milicic A</pubmed_authors><pubmed_authors>Brun J</pubmed_authors><pubmed_authors>Richter FC</pubmed_authors><pubmed_authors>Batchelor V</pubmed_authors><pubmed_authors>Bart VMT</pubmed_authors><pubmed_authors>Peppa D</pubmed_authors><pubmed_authors>Tellier M</pubmed_authors><pubmed_authors>Ladell K</pubmed_authors><pubmed_authors>Chapman L</pubmed_authors><pubmed_authors>Rehwinkel J</pubmed_authors></additional><is_claimable>false</is_claimable><name>The role and uses of antibodies in COVID-19 infections: a living review.</name><description>Coronavirus disease 2019 has generated a rapidly evolving field of research, with the global scientific community striving for solutions to the current pandemic. Characterizing humoral responses towards SARS-CoV-2, as well as closely related strains, will help determine whether antibodies are central to infection control, and aid the design of therapeutics and vaccine candidates. This review outlines the major aspects of SARS-CoV-2-specific antibody research to date, with a focus on the various prophylactic and therapeutic uses of antibodies to alleviate disease in addition to the potential of cross-reactive therapies and the implications of long-term immunity.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021</publication><modification>2025-05-18T11:26:03.598Z</modification><creation>2021-03-08T08:09:28Z</creation></dates><accession>S-EPMC7928637</accession><cross_references><pubmed>34192270</pubmed><doi>10.1093/oxfimm/iqab003</doi></cross_references></HashMap>